Q-omics provides the consensus-scored HSP90AB2P profile across patient tissues and cancer cell-line models. HSP90AB2P expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HSP90AB2P is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, HSP90AB2P RNA expression shows 18,316 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where HSP90AB2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSP90AB2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSP90AB2P survival associations across molecular data types. HSP90AB2P RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSP90AB2P RNA expression–survival associations across cancer types. High HSP90AB2P expression shows unfavorable associations in COAD, KIRP, LUAD, LIHC and BLCA, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HSP90AB2P RNA expression.
This table summarizes HSP90AB2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for HSP90AB2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSP90AB2P shows higher tumor expression in COAD, LIHC, LUAD, STAD, LUSC and HNSC. The COAD box plot shows higher HSP90AB2P RNA expression in tumor versus normal tissue (log2 FC = +1.214, t-test p < 0.001).
This table shows molecular features associated with HSP90AB2P in patient tissues and cancer cell lines. In patient samples, HSP90AB2P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, HSP90AB2P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS.
